Increased levels of unbound apo(a) which occur with muvalaplin treatment are not correlated with changes in biomarkers of cardiovascular or kidney disease. This is the main finding from a post hoc analysis of data from a Phase 2 trial of muvalaplin, an Lp(a) lowering agent in development that, in contrast to other Lp(a) targeting agents, is designed to block binding of apo(a) to apoB, thereby preventing Lp(a) formation.
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
